

The Not-So-Good Prognosis of Streptococcal Periprosthetic Joint Infection Managed by Implant Retention: The Results of a Large Multicenter Study

Jaime Lora-Tamayo^{*1,52}, Éric Senneville², Alba Ribera^{3,7,52}, Louis Bernard^{4,53}, Michel Dupon⁵, Valérie Zeller⁶, Ho Kwong Li⁷, Cédric Arvieux^{8,53}, Martin Clauss⁹, Ilker Uçkay¹⁰, Dace Vigante¹¹, Tristan Ferry¹², José Antonio Iribarren¹³, Trisha N. Peel¹⁴, Parham Sendi¹⁵, Nina Gorišek Miksić¹⁶, Dolores Rodríguez-Pardo^{17,52}, María Dolores del Toro^{18,52}, Marta Fernández-Sampedro^{19,52}, Ulrike Dapunt²⁰, Kaisa Huotari²¹, Joshua S. Davis²², Julián Palomino^{18,53}, Danielle Neut²³, Benjamin M. Clark²⁴, Thomas Gottlieb²⁵, Rihard Trebše²⁶, Alex Soriano^{27,52,54}, Alberto Bahamonde²⁸, Laura Guío^{29,52}, Alicia Rico³⁰, Mauro J. C. Salles³¹, M. José G. Pais³², Natividad Benito^{33,52,53}, Melchor Riera^{34,52}, Lucía Gómez³⁵, Craig A. Aboltins¹⁴, Jaime Esteban³⁶, Juan Pablo Horcajada³⁷, Karina O'Connell³⁸, Matteo Ferrari³⁹, Gábor Skaliczki⁴⁰, Rafael San Juan^{1,52}, Javier Cobo^{41,52}, Mar Sánchez-Somolinos^{42,52}, Antonio Ramos⁴³, Efthymia Giannitsioti⁴⁴, Alfredo Jover-Sáenz⁴⁵, Josu Mirena Baraia-Etxaburu⁴⁶, José María Barbero⁴⁷, Peter F. M. Choong⁴⁸, Nathalie Asseray^{49,53}, Séverine Ansart^{50,53}, Gwenael Le Moal^{51,53}, Werner Zimmerli⁹, Javier Ariza^{**3,52}, and the Group of Investigators for Streptococcal Prosthetic Joint Infection[†].

1. Unit of Infectious Diseases. Department of Internal Medicine. Hospital Universitario 12 de Octubre. Instituto de Investigación Hospital 12 de Octubre. Madrid, Spain
2. Department of Infectious Diseases. Gustave Dron Hospital of Tourcoing, France.
3. Department of Infectious Diseases. Hospital Universitario de Bellvitge. IDIBELL. Barcelona, Spain.
4. Department of Infectious Diseases. Hôpital Universitaire Bretonneau. Tours, France
5. Centre correspondant de prise en charge des Infections Ostéo-articulaires Complexes du Grand Sud-Ouest – CHU Bordeaux – France.
6. Centre de Référence des Infections Ostéo-Articulaires Complexes, Groupe Hospitalier Diaconesses Croix Saint Simon, Paris, France.
7. Bone Infection Unit, Nuffield Orthopaedic Centre, Oxford, United Kingdom.
8. Department of Infectious Diseases, Rennes University Hospital, Rennes, France.
9. Interdisciplinary Septic Surgical Unit, Kantonsspital Baselland, Liestal. Switzerland.
10. Department of Infectious Diseases. Hôpitaux Universitaires Genève. Geneva, Switzerland.
11. Hospital of Traumatology and Orthopedics. Riga, Latvia.
12. Department of Infectious and Tropical Diseases. Hôpital de la Croix-Rousse, Hospices Civils de Lyon. Lyon, France
13. Department of Infectious Diseases. Hospital Universitario Donostia. San Sebastián, Spain.
14. Department of Infectious Diseases. Saint Vincent's Public Hospital. Melbourne, Victoria, Australia.
15. Department of Infectious Diseases. University Hospital of Bern, Switzerland.
16. Infectious Diseases Department, University Clinical Center, Maribor, Slovenia.
17. Infectious Diseases Department. Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain
18. Clinical Unit of Infectious Diseases, Microbiology and Preventive Medicine. Institute of Biomedicine of Seville (Ibis). University of Seville. University Hospitals Virgen Macarena y Virgen del Rocío. Sevilla, Spain.
19. Department of Infectious Diseases. Hospital Universitario Marqués de Valdecilla, Santander, Spain.
20. Center for Orthopedics, Trauma Surgery and Spinal Cord Injury, Heidelberg University Hospital, Heidelberg, Germany.
21. Helsinki University Hospital. Helsinki, Finland.
22. Department of Infectious Diseases. John Hunter Hospital. Newcastle, New South Wales, Australia.
23. Department of Orthopedic Surgery and Department of Biomedical Engineering, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
24. Department of Infectious Diseases, Fiona Stanley Hospital, Western Australia, Australia.

25. Department of Microbiology and Infectious Diseases. Concord Hospital, Concord, New South Wales, Australia.
26. Service for Bone Infections. Valdoltra Orhtopaedic Hospital. Ankaran, Slovenia.
27. Department of Infectious Diseases. Hospital Clínic, Barcelona, Spain
28. Department of Internal Medicine. Hospital de El Bierzo, Ponferrada, Spain.
29. Unit of Infectious Diseases. Hospital de Cruces, Barakaldo, Spain.
30. Unit of Infectious Diseases, Department of Internal Medicine. Hospital Universitario La Paz. Madrid, Spain.
31. Unit of Infectious Diseases, Department of Internal Medicine. Santa Casa de Misericórdia de São Paulo, São Paulo, Brazil.
32. Unit of Infectious Diseases, Department of Internal Medicine. Hospital Universitario Lucus Augusti, Lugo, Spain.
33. Unit of Infectious Diseases, Hospital Universitari de la Santa Creu I Sant Pau. Institut d'Investigació Biomèdica Sant Pau. Universitat Autònoma de Barcelona, Barcelona, Spain.
34. Department of Internal Medicine. Hospital Son Espases, Palma de Mallorca, Spain.
35. Unit of Infectious Diseases. Hospital Universitari Mútua de Terrassa. Terrassa, Spain.
36. Department of Clinical Microbiology. IIS-Fundación Jiménez Díaz. Madrid, Spain.
37. Department of Infectious Diseases. Hospital del Mar. Barcelona, Spain.
38. Department of Clinical Microbiology. Beaumont Hospital, Dublin, Ireland.
39. Department of Orthopedics and Rehabilitation. Humanitas Research Hospital. Milano, Italy.
40. Department of Orthopedics, OrhopediClinic, Semmelweis University, Budapest, Hungary
41. Department of Infectious Diseases. Hospital Universitario Ramón y Cajal. IRYCIS. Madrid, Spain.
42. Department of Clinical Microbiology and Infectious Diseases. Hospital General Universitario Gregorio Marañón. Madrid, Spain.
43. Unit of Infectious Diseases, Department of Internal Medicine. Hospital Universitario Puerta de Hierro. Madrid, Spain.
44. Department of Infectious Diseases, 4th Department of Internal Medicine, NKUA, ATTIKON University General Hospital. Athens, Greece.
45. Department of Infectious Diseases. Hospital Universitari Arnau de Vilanova, Lleida, Spain
46. Department of Infectious Diseases. Hospital de Basurto, Bilbao, Spain.
47. Department of Internal Medicine. Hospital Universitario Príncipe de Asturias. Alcalá de Henares, Spain.
48. University of Melbourne. Department of Surgery and Department of Orthopaedic. St. Vincent's Hospital, Melbourne, Victoria, Australia.
49. Department of Infectious Diseases. Hôpital Universitaire Hôtel Dieu. Nantes, France.
50. Department of Infectious Diseases. Hôpital Universitaire La Cavale Blanche. Brest, France.
51. Department of Infectious Diseases. Hôpital Universitaire La Milettrie. Poitiers, France.
52. Red Española de Investigación en Patología Infecciosa (REIPI)
53. Centre de Référence pour les Infections Ostéo-Articulaires Complexes du Grand Ouest (CRIOGO)
54. ESCMID Study Group for Implant-Associated Infections (ESGIAI).

[†] see listing in acknowledgements

***Corresponding author**

Jaime Lora-Tamayo, MD, PhD
 Unit of Infectious Diseases, Department
 of Internal Medicine
 Hospital Universitario 12 de Octubre.
 Avenida de Córdoba s/n. 28041 Madrid.
 Tel. 0034 913908000
 e-mail: jaime@lora-tamayo.es

Running title: Streptococcal prosthetic joint infection

Summary

Rate of failure among 462 patients with streptococcal periprosthetic joint infection managed with implant retention was 42.1% (95% confidence interval:37.5%–46.7%).

Treatment with β -lactams was confirmed to improve the prognosis, which could be improved by the addition of rifampin.

ABSTRACT

Background: Streptococci are not an infrequent cause of periprosthetic joint infection (PJI). Management by debridement, antibiotics, and implant retention (DAIR) is thought to produce a good prognosis, but little is known about the real likelihood of success.

Methods: Retrospective, observational, multicenter, international study performed during 2003-2012. Eligible patients had a streptococcal PJI that was managed with DAIR. The primary endpoint was failure, defined as death related to infection, relapse/persistence of infection, or the need for salvage therapy.

Results: Overall, 462 cases were included (median age 72 years, 50% men). The most frequent species was *S.agalactiae* (34%), and 52% of all cases were hematogenous. Antibiotic treatment was primarily using β -lactams, and 37% of patients received rifampin. Outcomes were evaluable in 444 patients: failure occurred in 187 (42.1%, 95% confidence interval: 37.5%–46.7%) after a median of 62 days from debridement; patients without failure were followed for a median of 802 days. Independent predictors (hazard ratios) of failure were rheumatoid arthritis (2.36), late post-surgical infection (2.20), and bacteremia (1.69). Independent predictors of success were exchange of removable components (0.60), early use of rifampin (0.98 per day of treatment within the first 30 days), and long treatments (≥ 21 days) with β -lactams, either as monotherapy (0.48) or in combination with rifampin (0.34).

Conclusions: this is the largest series of streptococcal PJI managed by DAIR, showing a worse prognosis than previously reported. The beneficial effects of exchanging the removable components and of β -lactams are confirmed, and maybe also a potential benefit from adding rifampin.

Key words: biofilm, bone and joint infection, DAIR, rifampin,

BACKGROUND

Periprosthetic joint infection (PJI) is a dreaded complication of joint replacement [1,2]. Removal of the infected foreign body is the rule for any given device-associated infection. However, debridement, antibiotics, and implant retention (DAIR) may be attempted in some acute cases of PJI [2-4]. When strict selection of patients is followed, the success rate may reach >85% [4-7].

Streptococci are responsible for PJI in 4–12% of cases [8,9] especially in hematogenous infections [10,11]. Some studies have suggested that streptococcal PJI may have a more favorable outcome compared with other etiologies [12-14], but this has been contested by others [15]. In fact, the success rate of streptococcal PJI (mostly *Streptococcus agalactiae*) treated with DAIR varies from 22–100%, presumably depending on the selection criteria used [6,13,15-18] (Supplementary Table 1). Thus, the real success rate for patients managed by DAIR remains uncertain.

The optimal antimicrobial treatment for streptococcal PJI is also unknown. Current guidelines recommend the use of β -lactams [2,4], but these antibiotics may have a very high minimal biofilm eradication concentration [19,20]. The role of alternative compounds with a better antibiofilm profile [21] has not been consistently explored in clinical studies.

Our aim was to analyze the clinical presentations and outcomes of a large cohort of patients with streptococcal PJI managed by DAIR, focusing on the impact of antimicrobial therapy.

METHODS

Setting and Patients

This was a multicenter retrospective study performed in 52 hospitals from 15 nations between 2003 and 2012. Patients were included if they had suffered a PJI that was caused by streptococci and initially managed by DAIR. Eighty-one cases included here have previously been published [6,15,22].

PJI was defined according to IDSA guidelines as the presence of a sinus tract communicating with the prosthesis, acute inflammation on histologic examination, purulence surrounding the prosthesis, and/or ≥ 2 evaluable samples yielding the same organism [4]. Polymicrobial cases were also included if streptococci were isolated from the beginning, but we excluded cases of streptococcal superinfection. Microorganisms were identified following standard criteria [23], after samples had been inoculated in liquid and solid media and incubated for ≥ 7 days. Enterococci, obligate anaerobes (i.e. *Peptostreptococcus* spp) or nutritionally variant streptococci (i.e. *Abiotrophia* spp) were not included.

PJI was classified as early postoperative, if the symptoms began within the first 3 months after the prosthesis was placed, and late post-surgical, if they started thereafter. The episode was considered acute hematogenous, if it occurred after an uneventful postoperative course and after microbiologically confirmed or clinically suspected streptococcal bacteremia. A contiguous spread was considered, if the PJI occurred in a limb with either infectious cellulitis, or a soft tissue abscess. New radiographical signs of infection were taken as a surrogate marker of chronicity (i.e., periprosthetic radiolucency, bone sclerosis, or osteolytic lesions). Chronic renal failure

was defined as a baseline creatinine >150 µmol/L; immunosuppressant therapy was recorded if the patient received was receiving glucocorticoid or other immunosuppressant drug therapy

Data were recorded in a Microsoft-Access database. All cases were critically reviewed by one author (J.L-T.), and any doubts or inconsistencies were double-checked by the investigator at each hospital.

Clinical and Surgical Management

DAIR has been described elsewhere [2,3,24]. Briefly, it comprises thorough surgical debridement of all purulent collections and necrotic tissues surrounding the prosthesis. Mobile parts of the device (i.e. the polyethylene liner) are exchanged if feasible. DAIR is recommended in patients who meet the criteria proposed by the IDSA guidelines [4]. Patients with early postoperative (<1 month) or acute hematogenous PJI with ≤3 weeks of symptoms qualify for DAIR if they have a soundly fixed prosthesis, good periprosthetic soft tissues condition, and antibiotics are available with a reasonable activity against biofilm-embedded bacteria. In the present study, these criteria were not strictly met by many patients, and the decision to undergo DAIR was taken by individual medical group on a case by case basis.

Outcome and Follow-up

Patients were followed until death, treatment failure, removal or replacement of the prosthesis, or until loss to follow-up. *Overall Failure* was the primary endpoint and was considered in cases of: i) death related to the infection; ii) need for salvage therapy to

control the infection, including supplementary surgical debridements >30 days after the first debridement, prosthesis removal (due to any cause during the first year after debridement, or due to streptococcal persistence or relapse, or superinfection by other microorganisms), or the need for supplementary courses of antibiotics beyond the initially scheduled treatment (including chronic suppressive antimicrobial therapy); and/or iii) persistent signs of infection at the last visit or follow-up appointment.

Given the retrospective nature of this study, and to avoid a survivor bias when analyzing the impact of antimicrobial therapy, several failure dynamics were studied:

- *Early Failure* was considered to have occurred in patients who met the failure criteria within the first 30 days after surgical debridement.
- *Late Failure* was considered to have occurred in patients who met the failure criteria beyond the first 30 days after debridement, but who were still under antimicrobial therapy. In this group, only antimicrobials received during the first 30 days were analyzed.
- *Failure after Therapy* was considered to have occurred in patients who met the failure criteria once they had finished the scheduled therapy. In this analysis, the antibiotics received throughout treatment were included.

Statistical Analysis

Categorical parameters were compared with the χ^2 test or Fisher's exact test, and continuous variables were compared with the Mann–Whitney *U* test or Kruskal–Wallis test. Parameters associated with *Overall Failure*, *Late Failure*, and *Failure after Therapy* were identified by Kaplan–Meier curves (long-rank test), univariate, and multivariate

Cox regression. For the analysis of *Early Failure*, logistic regression were performed. All analyses were 2-tailed, and a *p* value <0.05 was considered statistically significant.

RESULTS

Description of the Series

Overall, 922 cases of PJI were recorded, of which 92 (10.0%) were excluded for various reasons, leaving a cohort of 830 cases. We initially managed 462 (55.7%) by DAIR, and these cases were used as the focus of this analysis (Supplementary Figure 1).

The median age was 72 years (interquartile range [IQR] 65–78 years), and 50% were men. The most frequent type of PJI was hematogenous (52%), which occurred more frequently in men, in patients with malignancy and in those with knee prostheses. Patients with hematogenous PJI more frequently presented with bacteremia and elevated temperature, along with higher leukocyte counts and C-reactive (CRP) protein levels (Table 1).

The most frequent species was *S. agalactiae* (159 cases [34.4%]) (Table 2). There were 63 (14%) polymicrobial infections which were typically postoperative (83%), presented less frequently with fever (51% vs 68%, *p*=0.007) and more frequently with a sinus tract (34% vs 10%, *p*<0.001), and had lower CRP levels (80 mg/L [IQR 41-150] vs 202 mg/L [IQR 110-291], *p*<0.001).

Baseline features, clinical presentation, and management were similar among the streptococcal species (Supplementary Table 2). Exceptions to this were the higher rate

of patients with rheumatoid arthritis among episodes caused by *S. pyogenes*, and the higher rate of chronic lung disease and malignancy in PJI due to *S. pneumoniae*.

Pneumococcal PJI was also more frequently hematogenous, occurred more frequently with knee prostheses, and presented with a higher leukocyte count. Penicillin minimum inhibitory concentration (MIC) was >0.125 mg/L in 24/425 cases (6%).

DAIR Management

Patients underwent debridement after a median of 5 days (IQR 2–13) from the onset of symptoms. Removable components were exchanged in 53% of cases, this being highly variable across participating centers (Supplementary Figure 2). The median number of different antimicrobial classes prescribed per patient was 2 (range 1–6). Patients were usually treated with β -lactams, which were given intravenously for a mean time of 21 days \pm 20 days. Rifampin-based combinations were significantly used (i.e. during >21 days) in 37% of patients, but this fraction was also highly variable across the participating hospitals (in those recruiting >10 patients, it ranged from 18–88%) (Supplementary Figure 2). Alternative antimicrobials such as fluoroquinolones, clindamycin, or linezolid were used less often (Supplementary Table 3). In patients not failing while on treatment, antimicrobial therapy was continued for a median of 91 days (IQR 58–171 days).

Outcome

The primary endpoint was evaluable in 444 patients (96.1%). *Overall Failure* occurred in 187 patients (42.1%, 95% confidence interval [95%CI]: 37.5%–46.7%) after a median of 62 days from debridement (IQR 25–160 days); by contrast, 257 patients (57.1%) did

not fail and were followed up for a median of 802 days (IQR 507–1339 days) (Figure 1-A). Success rates were highly variable among the participating centers (Supplementary Figure 2), with it ranging from 44% to 91% among hospitals recruiting >10 patients.

Independent predictors of a poor outcome were rheumatoid arthritis (Hazard Ratio [HR] 2.36), late post-surgical infection (HR 2.20), and bacteremia (HR 1.69). The exchange of removable components was independently associated with a favorable outcome (HR 0.60) (Table 3). No one streptococcal species was associated with a higher likelihood of Overall Failure, although a non-significant better prognosis was observed for *S.pneumoniae* (24% failure). A high penicillin MIC (>0.125 mg/L) was also not associated with failure. Also, polymicrobial cases were not associated with a higher likelihood of failure, even when *S.aureus* was involved (data not shown).

Late post-surgical infection was indeed a predictor of bad prognosis, when defined as onset of symptoms beginning >3 months after the prosthesis placement (Figure 1-C). Cases with symptoms beginning within the first and third month had a similar prognosis to that of cases with symptoms beginning within the first month after prosthesis placement. No relevant differences were observed in these two groups of patients (data not shown).

The failure rate was higher in patients not fulfilling the IDSA criteria for DAIR, namely 106/223 (48%) vs 81/221 (37%) (long-rank test, $p=0.017$) (Fig 1-B). Again, indication of DAIR according to the IDSA criteria was highly variable among participating centers (Supplementary Figure 2), ranging from 33% to 83% in those recruiting >10 patients.

Independent predictors of failure among patients meeting the IDSA criteria were rheumatoid arthritis (HR 2.46 [95%CI 1.34–4.53]), bacteremia (HR 1.92 [95%CI 1.22–3.02]), and male sex (HR 1.85 [95%CI 1.18–2.91]). Interestingly, the exchange of removable components during debridement was especially beneficial in patients not meeting the IDSA criteria (37% failures vs 62%, $p < 0.001$), in comparison with patients fulfilling them (failures 33% vs 39%, $p = 0.286$).

Failure Dynamics and Antimicrobial Therapy

Among the 187 patients who failed, 55 (29%) developed *Early Failure*, 71 (38%) developed *Late Failure*, and 61 developed *Failure after Therapy* (33%). Variables independently associated with Early Failure were age, rheumatoid arthritis, late post-surgical infection, bacteremia, and infection by *S.pyogenes* (Table 4).

Characteristics associated with *Late Failure* were male sex, immunosuppressant therapy, revision prosthesis, debridement delay >7 days, and the need for >1 debridement to control the infection. Failure was also associated with the early use of glycopeptides during >14 days. However, the addition of rifampin to treatment with glycopeptides neutralized this poor prognosis. The early use of rifampin plus fluoroquinolones also showed a trend toward a favorable outcome in the univariate analysis (HR 0.19, $p = 0.082$).

Late post-surgical infection was an independent predictor of *Failure after Therapy*, while the exchange of removable components was associated with a favorable outcome. The use of β -lactams for >21 days, both alone and combined with rifampin,

were independently associated with better outcomes (HR 0.48 and 0.34, respectively) (Figure 2).

The benefits of early treatment with rifampin were also observed for patients when treatment did not fail within the first 30 days after debridement (HR 0.98 per day of treatment, $p=0.034$) (Table 3).

DISCUSSION

This is the largest series assessing the management of streptococcal PJI by DAIR. Our results show an overall long-term likelihood of curing the infection and keeping the prosthesis of 57%. The large sample used in our study, the diversity of streptococcal species, and the high number of participating hospitals increase the external validity of our results.

Predictors of a poor outcome in this series were similar to those found in previous studies of PJI by staphylococci and GNB managed by DAIR. In previous reports, patients with bacteremia, needing >1 debridement, or with high CRP levels have shown to have a bad prognosis [24-29]. In our series, bacteremia and infection by *S.pyogenes* were independent predictors of *Early Failure*.

Otherwise, the streptococcal species presented a very similar pattern regarding clinical presentation and outcome, though *S.pneumoniae* presented more frequently as a hematogenous infection, and was usually associated with a better prognosis (non-significant).

The percentage of hematogenous infection in this series was notably high, when compared with PJI by *S.aureus* (52% vs 15%) [25]. Moreover, we cannot rule out that some late post-surgical infections were actually hematogenous. Although staphylococcal hematogenous PJI has been reported to carry a poor prognosis [25,30,31], in this study we did not find an association with failure, despite the higher association of hematogenous infection with bacteremia, fever, high levels of CRP, and a high leukocyte count. It is possible that the ability of β -lactams to clear bacteremia and planktonic infection in hematogenous PJI could be higher for streptococci than for staphylococci.

Univariate and multivariate analyses have shown that some debilitating baseline conditions are associated with a worse outcome. Taken together with our previous large series, rheumatoid arthritis, immunosuppressant therapy, and chronic renal insufficiency seem to be associated with a higher risk of treatment failure when attempting DAIR [25,27]. The exchange of removable components was associated with a favorable outcome, something that has also been observed in previous studies [25,32]. This is consistent with the physical removal of the biofilm, and probably stands as a surrogate marker of an exhaustive surgical debridement. Of note, this benefit was particularly observed in patients not fulfilling IDSA criteria for DAIR.

Unfortunately, the possibility of performing an accurate analysis of antimicrobial efficacy is impaired by the retrospective nature of this study, along with the heterogeneity of the therapeutic schedules. Still, the large size of our series allows for some interesting considerations.

β -lactams have classically been the preferred therapy for streptococcal infections, including PJI, providing very good activity for the initial planktonic phase of these infections [33]. However, once this initial phase has passed, the antibiofilm profile of these antimicrobials is questionable because, as with any antibiotic with a mechanism of action dependent on cell wall synthesis, they will become less effective against biofilm-embedded bacteria [34]. There is now strong evidence β -lactams have poor efficacy for staphylococcal and GNB PJI, especially when contrasted with other antibiotics that have superior antibiofilm profiles, such as rifampin against staphylococci or fluoroquinolones against GNB [25-27,35,36]. However, these findings have not been demonstrated in streptococcal PJI, which has been disregarded in those studies.

Our patients were mostly treated with β -lactams, in line with classic recommendations and routine clinical practice. The multivariate analysis concerning *Failure after Therapy* showed that this therapy was beneficial, with superiority over less effective alternatives like glycopeptides. This beneficial effect probably depended, in part, on the activity of β -lactams against planktonic bacteria in the first weeks of treatment [37]. Therefore, this contribution may be relevant to the outcome of PJI.

However, other data could indicate the suboptimal antibiofilm activity of β -lactams in our series, along with some evidence of a possible beneficial effect of rifampin. Among patients who completed a long course of treatment with β -lactams, we did not observe statistical differences among those also receiving rifampin or not, but a

tendency toward a better prognosis was found in those treated with combined therapy (10.0% failure rate vs 16.8%, Fig 2). In addition, the initial treatment with rifampin was also proved as an independent predictor of a favorable outcome (Table 4).

IDSA criteria for instituting DAIR were not met by all cases in this study. Consistent with previous studies, this allowed us to confirm the usefulness of these criteria for selecting suitable candidates for DAIR [6,7,25,27]. We were also able to test the effect of each of these criteria on the outcomes. In this regard, the duration of symptoms may be difficult to establish, especially in postoperative cases where pain and inflammation may overlap those of the post-surgical period. The age of the prosthesis may therefore be a more objective measure in such cases, consistent with the IDSA recommendation that patients undergo DAIR only if there is a short time between the prosthesis placement and debridement [4]. The definition of early postoperative PJI has varied over time in several landmark publications, ranging from 1 to 3 months [2,11,36], with the IDSA recommending that DAIR should be performed within 1 month after placing the prosthesis [4]. However, we have observed a similar prognosis for patients with postoperative infection whose symptoms began within the first month after prosthesis placement and those whose symptoms started between the first and third month (Fig 2). A similar finding was also observed for staphylococcal PJI [25], and it would emphasize this 3-month time limit over a more strict cutoff.

As mentioned, our analysis has the inherent limitations of retrospective studies. For instance, the influence of antibiotics was evaluated with continuous variables (i.e. days

of antibiotics), but also after arbitrarily categorizing these parameters (i.e., >21 days of treatment). Also, the possible relevance of endocarditis was not evaluated in this study. Finally, it has been already mentioned the significant heterogeneity of patients included across the participating institutions, especially regarding their management: the fulfillment of the IDSA criteria, the participation of different surgical teams or the decision on whether to use or not rifampin are all examples of this variability (supplementary figure 2). Still, these cases form a large cohort of patients with streptococcal PJI, all treated by DAIR. This has given us the opportunity to study their prognosis in the best and the worst possible clinical scenario, thus providing an overall perspective of the clinical problem.

In summary, we analyzed the largest series of streptococcal PJI managed by DAIR to date, and showed a modest prognosis of curing the infection and retaining the prosthesis. We conclude that classical treatment with β -lactams is probably ideal for fighting the planktonic component of the infection. We found a piece of evidence suggesting that addition of rifampin some days or weeks after debridement could improve the outcome, but this should be confirmed in further studies. IDSA criteria are a valid clinical tool for deciding DAIR, late post-surgical infection (i.e. symptoms beginning >3 months since prosthesis placement) being the most important contra-indication. The exchange of removable components during debridement stands as an independent predictor of a favourable outcome.

NOTES

ACKNOWLEDGMENTS

We thank Michael Maudsley (University of Barcelona) for reviewing the English manuscript.

FUNDING

J.L-T holds a clinical research contract “Sara Borrell” (CD14/00176) from the Instituto de Salud Carlos III (Spanish Ministry of Economy and Competitiveness). CRIOGO is funded by the French Ministry of Health. A.R. was supported by a research grant from the Bellvitge Biomedical Research Institute (IDIBELL). REIPI is supported by the Spanish Ministry of Economy and Competitiveness, Instituto de Salud Carlos III, and by the European Development Regional Fund “A way to achieve Europe”.

CONFLICT OF INTEREST

The authors declare not to have any conflict of interests.

List of collaborators/Group of Investigators for Streptococcal Prosthetic Joint Infection

This is a multicenter study. In each institution there are many researchers that have helped to make this study possible. We are deeply indebted to these collaborators, who are:

- Fernando Chaves, José Alberto Moreno-Beamud, Rafael Navarro Arribas (Hospital Universitario 12 de Octubre, Madrid, Spain)

- Sophie Nguyen (Gustave Dron Hospital of Tourcoing, France)
- Oscar Murillo, Xavier Cabo, Salvador Pedrero (Hospital Universitari de Bellvitge, Barcelona, Spain).
- Frédéric Dauchy, Hervé Dutronc, Bertille de Barbeyrac (Centre correspondant de prise en charge des Infections Ostéo-articulaires Complexes Du Grand Sud-Ouest - CHU Bordeaux – France)
- Matthew Scarborough, Martin McNally, Bridget Atkins (Bone Infection Unit, Nuffield Orthopaedic Centre, Oxford, United Kingdom)
- Pierre Tattevin, Marie Ghéno, Enora Ouamara-Digue (Rennes University Hospital, Rennes, France)
- Bernhard Kessler (Kantospital Baselland, Liestal, Switzerland)
- Sébastien Lustig, Florent Valour, Christian Chdiac (Hôpital de la Croix-Rousse, Hospices Civils de Lyon. Lyon, France)
- Miguel Ángel Goenaga, Asier Mitxelena, Enrique Moreno (Hospital Universitario Donostia, San Sebastián, Spain).
- Maja Bombek Ihan, Zmago Krajnc (University Clinical Center, Maribor, Slovenia).
- Carles Pigrau, Pablo S. Corona Pérez-Cardona (Hospital Universitari Vall d’Hebron, Barcelona, Spain).
- Cecilia Peñas Espinar, Ana Isabel Suárez, Miguel Muniain Ezcurra (University Hospitals Virgen Macarena y Virgen del Rocío. Sevilla, Spain).
- María Carmen Fariñas (Hospital Universitario Marqués de Valdecilla, Santander, Spain).
- Markku Vuorinen, Jarkko Leskinen (Helsinki University Hospital, Helsinki, Finland).

- Tristan Yolland, Mark Lowenthal (John Hunter Hospital, Newcastel, NSW, Australia).
- Julia Praena, Salvador Fornell, María-José Gómez (Hospital Universitario Virgen del Rocío, Sevilla, Spain).
- Paul C. Jutte (University Medical Center Groningen, Groningen, The Netherlands).
- Anže Mihelič, Rene Mihalič (Valdoltra Orthopaedic Hospital, Ankaran, Slovenia).
- Guillem Bori, Laura Morata, Eduard Tornero (Hospital Clínic, Barcelona, Spain).
- Carlos Fuster Foz, Susana García Villabrille, Marta Novoa (Hospital de El Bierzo, Ponferrada, Spain).
- Emerson K. Honda, Ricardo de Paula Leite Cury (Santa Casa de Misericórdia, São Paulo, Brazil).
- Juan Corredoira (Hospital Universitario Lucus Augusti, Lugo, Spain)
- Pere Coll, Isabel Mur, Xavier Crusi (Hospital de la Santa Creu i Sant Pau, Barcelona, Spain).
- Antonio Ramírez, Francisco Montaner (Hospital Universitario Son Espasses, Palma de Mallorca, Spain).
- Eva Cuchí (Catlab, Viladecavalls, Barcelona, Spain), Alfredo Matamala (Hospital Universitari Mútua de Terrassa, Spain).
- Antonio Blanco, Joaquín García-Cañete, Raúl Parrón (Fundación Jiménez Díaz, Madrid, Spain)
- Luisa Sorlí, Lluís Puig, Nuria Prim (Hospital del Mar, Barcelona, Spain)
- Botond Lakatos, Gyula Prinz (Orthopedic Clinic, Semmelweis University Budapest, Hungary)

- Gema Gresco, Patricia Ruiz-Garbajosa (Hospital Universitario Ramón y Cajal, Madrid, Spain)
- Mercedes Marín Arriaza (Hospital Universitario Gregorio Marañón, Madrid, Spain)
- Isabel Sánchez-Romero, Miguel Ángel García Viejo, Jesús Campo Loarte (Hospital Universitario Puerta de Hierro, Madrid, Spain).
- Antonios Papadopoulos (ATTIKON University General Hospital, Athens, Greece).
- María Fernanda Ramírez-Hidalgo, Laura Prats-Gispert, Ferran Pérez-Villar (Hospital Universitari Arnau de Vilanova, Lleida, Spain)
- Juan Romanyk (Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Madrid, Spain).
- Guido Grappiolo, Mattia Loppini, Marco Scardino (Humanitas Research Hospital, Milan, Italy).
- Elaine Cheong, Genevieve McKew, Amarita Ronnachit (Concord Hospital, Concord, NSW, Australia)

REFERENCES

1. Darouiche RO. Treatment of infections associated with surgical implants. *The New England journal of medicine* **2004**; 350(14): 1422-9.
2. Zimmerli W, Trampuz A, Ochsner PE. Prosthetic-joint infections. *The New England journal of medicine* **2004**; 351(16): 1645-54.
3. Byren I, Bejon P, Atkins BL, et al. One hundred and twelve infected arthroplasties treated with 'DAIR' (debridement, antibiotics and implant retention): antibiotic duration and outcome. *The Journal of antimicrobial chemotherapy* **2009**; 63(6): 1264-71.
4. Osmon DR, Berbari EF, Berendt AR, et al. Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America. *Clin Infect Dis* **2013**; 56(1): e1-e25.
5. Laffer RR, Graber P, Ochsner PE, Zimmerli W. Outcome of prosthetic knee-associated infection: evaluation of 40 consecutive episodes at a single centre. *Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases* **2006**; 12(5): 433-9.
6. Sendi P, Christensson B, Uckay I, et al. Group B streptococcus in prosthetic hip and knee joint-associated infections. *The Journal of hospital infection* **2011**; 79(1): 64-9.
7. Tschudin-Sutter S, Frei R, Dangel M, et al. Validation of a treatment algorithm for orthopaedic implant-related infections with device-retention-results from a prospective observational cohort study. *Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases* **2016**; 22(5): 457 e1-9.
8. Benito N, Franco M, Ribera A, et al. Time trends in the aetiology of prosthetic joint infections: a multicentre cohort study. *Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases* **2016**; 22(8): 732 e1-8.
9. Peel TN, Cheng AC, Buising KL, Choong PF. Microbiological aetiology, epidemiology, and clinical profile of prosthetic joint infections: are current antibiotic prophylaxis guidelines effective? *Antimicrobial agents and chemotherapy* **2012**; 56(5): 2386-91.
10. Marculescu CE, Berbari EF, Hanssen AD, et al. Outcome of prosthetic joint infections treated with debridement and retention of components. *Clin Infect Dis* **2006**; 42(4): 471-8.
11. Tsukayama DT, Estrada R, Gustilo RB. Infection after total hip arthroplasty. A study of the treatment of one hundred and six infections. *The Journal of bone and joint surgery American volume* **1996**; 78(4): 512-23.
12. Betz M, Abrassart S, Vaudaux P, et al. Increased risk of joint failure in hip prostheses infected with *Staphylococcus aureus* treated with debridement, antibiotics and implant retention compared to *Streptococcus*. *International orthopaedics* **2015**; 39(3): 397-401.
13. Everts RJ, Chambers ST, Murdoch DR, Rothwell AG, McKie J. Successful antimicrobial therapy and implant retention for streptococcal infection of prosthetic joints. *ANZ journal of surgery* **2004**; 74(4): 210-4.
14. Zurcher-Pfund L, Uckay I, Legout L, Gamulin A, Vaudaux P, Peter R. Pathogen-driven decision for implant retention in the management of infected total knee prostheses. *International orthopaedics* **2013**; 37(8): 1471-5.

15. Zeller V, Lavigne M, Biau D, et al. Outcome of group B streptococcal prosthetic hip infections compared to that of other bacterial infections. *Joint, bone, spine : revue du rhumatisme* **2009**; 76(5): 491-6.
16. Corvec S, Illiaquer M, Touchais S, et al. Clinical features of group B Streptococcus prosthetic joint infections and molecular characterization of isolates. *Journal of clinical microbiology* **2011**; 49(1): 380-2.
17. Duggan JM, Georgiadis G, VanGorp C, Kleshinski J. Group B streptococcal prosthetic joint infections. *Journal of the Southern Orthopaedic Association* **2001**; 10(4): 209-14; discussion 14.
18. Meehan AM, Osmon DR, Duffy MC, Hanssen AD, Keating MR. Outcome of penicillin-susceptible streptococcal prosthetic joint infection treated with debridement and retention of the prosthesis. *Clin Infect Dis* **2003**; 36(7): 845-9.
19. del Prado G, Ruiz V, Naves P, Rodriguez-Cerrato V, Soriano F, del Carmen Ponte M. Biofilm formation by Streptococcus pneumoniae strains and effects of human serum albumin, ibuprofen, N-acetyl-l-cysteine, amoxicillin, erythromycin, and levofloxacin. *Diagnostic microbiology and infectious disease* **2010**; 67(4): 311-8.
20. Olson ME, Ceri H, Morck DW, Buret AG, Read RR. Biofilm bacteria: formation and comparative susceptibility to antibiotics. *Canadian journal of veterinary research = Revue canadienne de recherche veterinaire* **2002**; 66(2): 86-92.
21. Garcia-Castillo M, Morosini MI, Valverde A, et al. Differences in biofilm development and antibiotic susceptibility among Streptococcus pneumoniae isolates from cystic fibrosis samples and blood cultures. *The Journal of antimicrobial chemotherapy* **2007**; 59(2): 301-4.
22. Fiaux E, Titecat M, Robineau O, et al. Outcome of patients with streptococcal prosthetic joint infections with special reference to rifampicin combinations. *BMC infectious diseases* **2016**; 16(1): 568.
23. Murray PR BE, Jorgesen JH, Landry ML, Pfaller MA. *Manual of Clinical Microbiology*. 9th ed. Washington, DC: ASM Press, **2007**.
24. Brandt CM, Sistrunk WW, Duffy MC, et al. Staphylococcus aureus prosthetic joint infection treated with debridement and prosthesis retention. *Clin Infect Dis* **1997**; 24(5): 914-9.
25. Lora-Tamayo J, Murillo O, Iribarren JA, et al. A large multicenter study of methicillin-susceptible and methicillin-resistant Staphylococcus aureus prosthetic joint infections managed with implant retention. *Clin Infect Dis* **2013**; 56(2): 182-94.
26. Martinez-Pastor JC, Munoz-Mahamud E, Vilchez F, et al. Outcome of acute prosthetic joint infections due to gram-negative bacilli treated with open debridement and retention of the prosthesis. *Antimicrobial agents and chemotherapy* **2009**; 53(11): 4772-7.
27. Rodriguez-Pardo D, Pigrau C, Lora-Tamayo J, et al. Gram-negative prosthetic joint infection: outcome of a debridement, antibiotics and implant retention approach. A large multicentre study. *Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases* **2014**; 20(11): O911-9.
28. Vilchez F, Martinez-Pastor JC, Garcia-Ramiro S, et al. Outcome and predictors of treatment failure in early post-surgical prosthetic joint infections due to Staphylococcus aureus treated with debridement. *Clinical microbiology and*

- infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases **2011**; 17(3): 439-44.
29. Tornero E, Martinez-Pastor JC, Bori G, et al. Risk factors for failure in early prosthetic joint infection treated with debridement. Influence of etiology and antibiotic treatment. *Journal of applied biomaterials & functional materials* **2014**; 12(3): 129-34.
 30. Sendi P, Banderet F, Graber P, Zimmerli W. Clinical comparison between exogenous and haematogenous periprosthetic joint infections caused by *Staphylococcus aureus*. *Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases* **2011**; 17(7): 1098-100.
 31. Vilchez F, Martinez-Pastor JC, Garcia-Ramiro S, et al. Efficacy of debridement in hematogenous and early post-surgical prosthetic joint infections. *The International journal of artificial organs* **2011**; 34(9): 863-9.
 32. Choi HR, von Knoch F, Zurakowski D, Nelson SB, Malchau H. Can implant retention be recommended for treatment of infected TKA? *Clinical orthopaedics and related research* **2011**; 469(4): 961-9.
 33. Baker CN, Thornsberry C, Facklam RR. Synergism, killing kinetics, and antimicrobial susceptibility of group A and B streptococci. *Antimicrobial agents and chemotherapy* **1981**; 19(5): 716-25.
 34. Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. *Science* **1999**; 284(5418): 1318-22.
 35. Senneville E, Joulie D, Legout L, et al. Outcome and predictors of treatment failure in total hip/knee prosthetic joint infections due to *Staphylococcus aureus*. *Clin Infect Dis* **2011**; 53(4): 334-40.
 36. Zimmerli W, Widmer AF, Blatter M, Frei R, Ochsner PE. Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign-Body Infection (FBI) Study Group. *JAMA* **1998**; 279(19): 1537-41.
 37. Sendi P, Zimmerli W. Antimicrobial treatment concepts for orthopaedic device-related infection. *Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases* **2012**; 18(12): 1176-84.

Figure 1 – Kaplan-Meier curves of patients with streptococcal periprosthetic joint infection according to the criteria for indicating debridement and implant retention

A – Kaplan-Meier curve of all evaluable patients (n=444, 187 failures). Causes of failure were due to the streptococcal infection in 147 cases (79%), the other reasons being prosthesis removal due to orthopedic causes (15 patients [8%]), and superinfection by other microorganisms (25 cases [13%]). Death related to PJI was observed in 11 cases (2%).

B – Black continuous line: patients meeting IDSA criteria for DAIR (see text): 81 failures in 221 episodes of infection; grey dotted line: patients not meeting IDSA criteria for DAIR: 106 failures in 223 episodes of infection; long-rank test, $p = 0.017$. Reasons for not fulfilling the IDSA criteria were (more than 1 motive per patient is possible): in 67 patients (30%) symptoms duration was longer than 21 days; 90 patients (40%) had a post-surgical infection with symptoms beginning beyond the first month after the placement of the prosthesis; 61 patients (27%) presented with a sinus tract; and in 80 cases (36%) there were radiographic signs of prosthesis loosening and/or chronic infection.

C - post-surgical cases (i.e., non-hematogenous cases) (n=189, 82 failures): black continuous line: cases with symptoms beginning within the first 30 days after the placement of the prosthesis (n=78, 25 failures); grey continuous line: cases with symptoms beginning within 31 and 90 days after the placement of the prosthesis (n=41, 13 failures); black dotted line: cases with symptoms beginning beyond 90 days after the placement of the prosthesis (n=70, 44 failures). Long-rank test, $p < 0.001$.

Figure 2 – Prognostic after the end of therapy according to the antibiotic treatment

Analysis performed in cases that did not fail during treatment (n=318, failures = 61). Black continuous line: patients treated during >21 days with β -lactams + rifampin (n=60, failures=6); black dotted line: patients treated during > 21 days with β -lactams, but no rifampin (n=154, failures=26); grey continuous line: patients treated >21 days with a rifampin-based combination other than β -lactams plus rifampin (n=48; failures=10); grey dotted line: patients who did not receive either β -lactams or rifampin for > 21 days (n=56; failures=19). Comparisons calculated with the Long-rank test. The comparison of these 4 treatment regimes showed similar trends when the analysis was stratified for patients meeting and not meeting IDSA criteria, and for patients who did and did not undergo exchange of removable components during debridement.

Table 1 – Baseline features, clinical presentation, surgical management and outcome and comparative analysis of hematogenous and non-hematogenous cases

	All patients (n=462)	Non-hematogenous cases (n=220)	Hematogenous cases (n=242)	p
Baseline features				
Sex (men)	232 (50%)	121 (45%)	111 (54%)	0.050
Age (years) [^]	72 (65-78)	72 (64-78)	72 (65-78)	0.986
Diabetes	111 (24%)	50 (23%)	61 (25%)	0.533
Renal chronic disease	45 (10%)	20 (9%)	25 (10%)	0.654
Rheumatoid arthritis	37 (8%)	15 (7%)	22 (9%)	0.369
Immunosuppressive therapy	49 (11%)	22 (10%)	27 (11%)	0.687
Malignancy	29 (6%)	7 (3%)	22 (9%)	0.009
Liver cirrhosis	19 (4%)	9 (4%)	10 (4%)	0.982
Chronic lung disease	56 (12%)	27 (12%)	29 (12%)	0.924
Chronic heart disease	128 (28%)	54 (25%)	74 (31%)	0.148
Prosthesis location (knee)	273 (59%)	117 (53%)	156 (65%)	0.014
Revision prosthesis	114 (25%)	48 (22%)	66 (27%)	0.174
Clinical presentation and microbiological data				
Temperature >37 ^o C	300 (66%)	110 (51%)	190 (80%)	<0.001
Sinus tract	62 (14%)	46 (21%)	16 (7%)	<0.001
Leukocyte count (x10E9/L) [^]	12.0 (8.5-15.4)	11.0 (7.3-14.6)	13.0 (9.6-16.0)	0.001
C-reactive protein at diagnosis (mg/L) [^]	186 (85-283)	135 (55-230)	234 (130-305)	<0.001
Rx signs of infection	85 (18%)	41 (19%)	44 (18%)	0.900
Bacteremia	138 (31%)	35 (17%)	103 (45%)	<0.001
Penicillin MIC >0.125 mg/L §	24/425 (6%)	15 (8%)	9 (4%)	0.113
Polymicrobial infection	63 (14%)	52 (24%)	11 (5%)	<0.001
Surgical management				
Time to debridement (days) ^{^φ}	5 (2-13)	5 (2-16)	5 (2-12)	0.688
Exchange of removable components ^{&}	220/418 (53%)	100/200 (50%)	120/218 (55%)	0.302
Need for ≥2 debridements	42 (9%)	21 (10%)	21 (9%)	0.797
Outcome‡				
Overall failure	187/444 (42%)	92/210 (44%)	95/234 (41%)	0.494
Early failure‡	55/187 (29%)	25/92 (27%)	30/95 (32%)	0.509
Late failure‡	71/187 (38%)	34/92 (37%)	37/95 (39%)	0.779
Failure after therapy ‡	61/187 (33%)	33/92 (36%)	28/95 (30%)	0.351

Data expressed as count and (percentage) except for [^]continuous variables (median and interquartile range). MIC: minimal inhibitory concentration. ^φTime from onset of symptoms to surgical debridement. [&]Data available in 418 cases. [‡]444 patients evaluable for outcome, percentages given over the whole of failures.

Table 2 – Etiology of 462 episodes of streptococcal periprosthetic joint infection

<i>Streptococcus</i>		
<i>S. agalactiae</i>		159
<i>S. pyogenes</i>		36 (7.8%)
<i>S. pneumoniae</i>		21 (4.5%)
Other large-colony β -haemolytic streptococci		121
<i>S. dysgalactiae</i>	49	
Group G streptococci	40 (8.7%)	
Other β -haemolytic streptococci	28 (6.1%)	
<i>S. equisimilis</i>	4 (0.9%)	
<i>S. anginosus</i> group		32 (6.9%)
<i>S. anginosus</i>	17 (3.7%)	
<i>S. constellatus</i>	8 (1.7%)	
<i>S. milleri</i>	4 (0.9%)	
<i>S. intermedius</i>	3 (0.6%)	
Viridans group		86 (18.6%)
Unspecified viridans streptococci	25 (5.4%)	
<i>S. mitis</i>	25 (5.4%)	
<i>S. oralis</i>	17 (3.7%)	
<i>S. sanguis</i>	10 (2.2%)	
<i>S. salivarius</i>	4 (0.9%)	
<i>S. gordonii</i>	2 (0.4%)	
<i>S. mutans</i>	2 (0.4%)	
<i>S. parasanguis</i>	1 (0.2%)	
Other streptococci		7 (1.5%)
<i>S. bovis</i>	6 (1.3%)	
<i>S. canis</i>	1 (0.2%)	
Other microorganisms (polymicrobial episodes)		
Gram positive microorganisms		59
<i>Staphylococcus aureus</i>	29	
Coagulase-negative staphylococci [^]	15	
<i>Enterococcus faecalis</i>	7	
<i>Corynebacterium striatum</i> [^]	2	
Other Gram-positive microorganisms [*]	6	
Gram negative microorganisms		19
Enterobacteriaceae [†]	15	
Non-fermentative Gram-negative	2	
Anaerobe Gram-negative	2	

*includes *Aerococcus viridans* (n=1), *Arcanobacterium haemolyticus* (n=1), *Bacillus* spp (n=2), *Lactobacillus acidophilus* (n=1) and *Peptostreptococcus* spp (n=1); ** includes *Pseudomonas aeruginosa* (n=1), *Acinetobacter baumannii* (n=1); † includes *Escherichia coli* (n=5), *Klebsiella pneumoniae* (n=1), *Enterobacter cloacae* (n=4), *Proteus mirabilis* (n=3), *Serratia* sp (n=1), and *Citrobacter* sp (n=1); ‡ includes *Veillonella* spp, and *Prevotella* spp

Table 3 – Predictors of Overall Failure and Influence of Early Antibiotic

		All evaluable cases – Overall Failure (n=444, 187 failures)					Evaluable cases not failing within the first 30 days (n=389, 132 failures)				
Variable	Categories	Failures/n	HR (95%CI)	P	aHR (95%CI)	P	Failures/n	HR (95%CI)	P	aHR (95%CI)	P
Sex	Female	90/225	0.86 (0.65-1.14)	0.30			60/195	0.75 (0.53-1.06)	0.10	-	-
	Male*	97/219					72/194				
Age (per year)	-	-	1.00 (0.99-1.01)	0.93			-	0.99 (0.98-1.01)	0.32		
Diabetes	Yes	50/108	1.16 (0.84-1.60)	0.38			36/94	1.20 (0.82-1.76)	0.36		
	No*	137/336					96/295				
Renal Chronic Disease	Yes	24/44	1.58 (1.03-2.43)	0.05	1.55 (0.97-2.48)	0.07	16/36	1.57 (0.93-2.65)	0.09	-	-
	No*	163/400					116/353				
Rheumatoid arthritis	Yes	24/37	2.23 (1.45-3.43)	<0.01	2.36 (1.50-3.72)	<0.01	14/27	2.04 (1.17-3.54)	0.02	-	-
	No*	163/407					118/362				
Immunosuppressive therapy	Yes	29/48	1.86 (1.25-2.76)	<0.01	-	-	21/40	2.08 (1.31-3.32)	<0.01	1.66 (0.99-2.18)	0.055
	No*	158/396					111/349				
Malignancy	Yes	11/28	0.90 (0.49-1.66)	0.73			10/27	1.20 (0.63-2.29)	0.59		
	No*	176/416					122/362				
Prosthesis location	Knee	116/263	1.05 (0.95-1.16)	0.31			82/229	1.09 (0.91-1.29)	0.36		
	Other*	71/181					50/160				
Revision prosthesis	Yes	60/112	1.60 (1.18-2.17)	<0.01	1.37 (0.98-1.90)	0.06	42/94	1.66 (1.15-2.40)	<0.01	1.47 (0.99-2.18)	0.06
	No*	127/332					90/295				
Hematogenous infection	Yes	95/234	0.90 (0.68-1.20)	0.48			65/204	0.84 (0.60-1.18)	0.32		
	No*	92/210					67/185				
Late post-surgical infection	Yes	44/70	1.41 (1.19-1.67)	<0.01	2.20 (1.51-3.20)	<0.01	31/57	1.28 (1.12-1.46)	<0.01	1.69 (1.10-2.60)	0.02
	No*	143/374					101/332				
Temperature >37 ⁰ C	Yes	122/288	1.08 (0.79-1.46)	0.65			85/251	1.05 (0.73-1.52)	0.78		
	No*	60/149					42/132				
Sinus tract	Yes	27/61	1.12 (0.75-1.69)	0.58			21/55	1.29 (0.81-2.06)	0.30		
	No*	155/378					107/330				
Rx signs of infection	Yes	39/80	1.08 (0.99-1.19)	0.11			25/66	1.21 (0.77-1.91)	0.42		
	No*	98/251					72/225				
Leukocytes (per unit/μL)		-	1.00 (1.00-1.00)	0.21			-	1.00 (1.00-1.00)	0.11		
C-reactive protein	Per mg/L	-	1.00 (1.00-1.00)	0.91			-	1.00 (1.00-1.00)	0.76		
Penicillin MIC	>0.125 mg/L	8/23	0.80 (0.40-1.63)	0.53			4/19	0.58 (0.21-1.56)	0.24		
	≤0.125 mg/L*	161/384					111/334				

Bacteriemia	Yes	63/132	1.44 (1.06-1.96)	0.02	1.69 (1.19-2.40)	<0.01	39/108	1.23 (0.84-1.79)	0.30		
	No*	110/290					83/263				
Polymicrobial infection	Yes	28/59	1.17 (0.78-1.74)	0.46			21/52	1.27 (0.80-2.03)	0.32		
	No*	159/385					111/337				
Time to debridement†	Per day	-	1.00 (1.00-1.00)	0.06	-	-	-	1.00 (1.00-1.00)	0.01	1.00 (1.00-1.00)	0.05
	>7 days	82/173	1.28 (0.96-1.71)	0.09			61/152	1.45 (1.03-2.05)	0.03		
	≤7 days*	105/271					71/237				
	>21 days	35/67	1.33 (0.92-1.92)	0.14			27/59	1.51 (0.99-2.31)	0.07		
	≤21 days*	152/377					105/330				
Polyethylene exchange	Yes	73/211	0.59 (0.44-0.80)	<0.01	0.60 (0.44-0.81)	<0.01	53/191	0.60 (0.42-0.86)	<0.01	0.65 (0.50-0.93)	0.02
	No*	98/190					68/160				
Need for ≥2 debridements	Yes	41/80	1.41 (1.00-2.00)	0.05	1.38 (0.96-1.99)	0.08	30/69	1.53 (1.02-2.30)	0.05	1.68 (1.10-2.57)	0.02
	No*	146/364					102/320				
Treatment with rifampin‡	Per day	-	-				-	0.99 (0.97-1.00)	0.05	0.98 (0.96-0.998)	0.03
	>14 days	-	-				33/116	0.72 (0.48-1.06)	0.09		
	≤14* days	-	-				99/273				
Treatment with β-lactams‡	Per day	-	-				-	0.99 (0.98-1.01)	0.99		
	>14 days	-	-				87/270	0.85 (0.59-1.22)	0.39		
	≤14* days	-	-				45/119				
Treatment with glycopeptides‡	Days	-	-				-	1.04 (1.02-1.06)	<0.01	1.04 (1.02-1.06)	<0.01
	>14 days	-	-				16/29	2.37 (1.40-4.00)	<0.01		
	≤14* days	-	-				116/360				
Treatment with co-trimoxazole‡	Days	-	-				-	1.03 (1.00-1.06)	0.04	1.04 (1.002-1.08)	0.04
	>14 days	-	-				6/9	2.33 (1.03-5.30)	0.04		
	≤14* days	-	-				126/380				

HR: Hazard Ratio; aHR: adjusted Hazard Ratio. 95%CI: 95% confidence intervals. CPR: C-reactive protein. MIC: minimal inhibitory concentration. * reference category. †Time from onset of symptoms to surgical debridement‡Treatments considered are those received within the first 30 days after surgical debridement. Overall analysis does not include the influence of antibiotics in order to avoid survivors bias. The initial model of the multivariate analyses was built with variables with a P value ≤ 0.10 in the univariate analysis, and then selected with a stepwise backward process (variables excluded during this process are marked as “-“).

Table 4 – Univariate and multivariate analysis of parameters predicting Early Failure, Late Failure and Failure After Therapy

	Early failure (n=444, 55 failures) ^a			Late Failure (n=389, 71 failures) ^b			Failure After Therapy (N=318, 61 failures)			
	OR (CI95%)	<i>p</i>	aOR (95%CI)	<i>p</i>	HR (95%CI)	<i>p</i>	aHR (CI95%)	<i>p</i>	aHR (CI95%)	<i>p</i>
Sex (female)	1.19 (0.68-2.10)	0.540			0.50 (0.31-0.81)	0.004	0.51 (0.30-0.85)	0.009	1.16 (0.69-1.92)	0.572
Age (per year)	1.03 (0.99-1.01)	0.076	1.04 (1.00-1.07)	0.027	1.00 (0.98-1.02)	0.995			0.99 (0.97-1.01)	0.348
Rheumatoid arthritis	2.98 (1.35-6.56)	0.007	3.33 (1.40-7.93)	0.007	2.95 (1.55-5.62)	0.004	-	-	1.19 (0.37-3.81)	0.772
Immunosuppressive therapy	1.49 (0.66-3.66)	0.343			2.76 (1.56-4.89)	0.002	2.64 (1.46-4.79)	0.001	1.51 (0.65-3.51)	0.363
Renal chronic disease	1.67 (0.73-3.81)	0.223			1.99 (1.05-3.79)	0.053	-	-	1.17 (0.47-2.91)	0.746
Prosthesis location (knee)	1.04 (0.86-1.26)	0.677			0.98 (0.83-1.14)	0.753			1.18 (0.98-1.41)	0.073
Revision prosthesis	1.53 (0.83-2.81)	0.173			1.78 (1.09-2.91)	0.027	1.77 (1.07-2.93)	0.027	1.56 (0.90-2.70)	0.129
Chronic post-surgical inf.	1.212 (0.97-1.23)	0.091	1.41 (1.10-1.81)	0.007	1.12 (0.92-1.37)	0.256			1.47 (1.22-1.77)	<0.001
Sinus tract	0.75 (0.31-1.84)	0.529			1.05 (0.54-2.06)	0.881			1.61 (0.84-3.11)	0.175
Bacteremia	2.17 (1.20-3.92)	0.011	2.23 (1.80-4.20)	0.014	1.24 (0.74-2.06)	0.420			1.23 (0.70-2.19)	0.478
Rx signs of infection	1.16 (0.98-1.39)	0.091	-	-	0.77 (0.40-1.48)	0.421			2.21 (1.14-4.30)	0.025
Infection by <i>S. pyogenes</i>	3.10 (1.41-6.85)	0.005	3.31 (1.41-7.77)	0.006	0.60 (0.19-1.92)	0.357			1.11 (0.45-2.78)	0.821
Infection by viridians streptococ	0.71 (0.32-1.57)	0.401			1.60 (0.94-2.70)	0.094	-	-	1.01 (0.51-1.98)	0.987
Polymicrobial infection	0.95 (0.41-2.20)	0.896			1.33 (0.71-2.47)	0.385			1.23 (0.61-2.49)	0.579
Time to debridement (>7 days) [†]	0.96 (0.54-1.72)	0.899			1.60 (1.00-2.54) [†]	0.050	1.70 (1.05-2.75)	0.033	1.33 (0.80-2.20)	0.281
Exchange of polyethylene	0.56 (0.31-1.02)	0.059	-	-	0.75 (0.46-1.21)	0.234			0.45 (0.26-0.77)	0.033
Need for ≥ 2 debridements	1.16 (0.57-2.36)	0.683			2.26 (1.63-4.36)	<0.001	2.45 (1.45-4.15)	0.001	0.60 (0.26-1.40)	0.206
Antimicrobial therapy [‡]										
B-lactams (without rifampin)	-	-			1.41 (0.88-2.27)	0.155			0.62 (0.37-1.03)	0.061
β-lactams + rifampin	-	-			0.89 (0.47-1.70)	0.724			0.42 (0.18-0.98)	0.025
Quinolones + rifampin	-	-			0.19 (0.03-1.36)	0.082	0.21 (0.03-1.54)	0.125	1.03 (0.45-2.40)	0.940
Glycopeptides without rifampin	-	-			3.97 (2.08-7.58)	<0.001	2.82 (1.43-5.53)	0.003	4.25 (1.32-13.7)	0.015
Duration of therapy > 120 day	-	-			-	-			0.54 (0.29-0.90)	0.046

OR: odds ratio; aOR: adjusted odds ratio; 95%CI: 95% confidence interval; HR: hazard ratio; aHR: adjusted hazard ratio. [†]Time to debridement: time from onset of symptoms to the first surgical debridement. Initial models of multivariate analyses were built with variables with a *P* value <0.10 in the univariate analysis, and then selected with a stepwise backward process.

^a Early Failure: the initial multivariate model included age, rheumatoid arthritis, late post-surgical infections, Rx signs of infection, infection by *S. pyogenes*, and bacteremia.

^b Late Failure: the initial multivariate model included sex, rheumatoid arthritis, immunosuppressant therapy, chronic renal disease, infection by *S. viridians*, time to debridement, need for ≥ 2 debridements, treatment with quinolones plus rifampin, and treatment with glycopeptides without rifampin. ‡ Treatments included in this analysis are those received during the first 30 days after debridement, and are considered if they were administered for at least 15 days.

^c Failure After Therapy: the initial multivariate model included prosthesis location, late post-surgical infection, Rx signs of infection, exchange of removable components (i.e. polyethylene liner), treatment with beta-lactams (without rifampin), treatment with beta-lactams plus rifampin, and treatment with glycopeptides without rifampin. ‡ Treatments included in this analysis are those received during the whole period of treatment, both orally and intravenously, and are considered if they were administered for at least 22 days.

Figure 1




Figure 2

